Reader-dependent functional duality of FTO: a context-switching node at the intersection of immune evasion and therapeutic resistance - Report - MDSpire

Context-Dependent Functional Versatility of FTO: A Key Player in Immune Evasion and Resistance to Therapy

  • By

  • WenJie Tian

  • Bin Xie

  • Peng Zhan

  • July 20, 2026

Share

Clinical Report: Context-Dependent Functional Versatility of FTO

Overview

The fat mass and obesity-associated protein (FTO) functions as a context-dependent epitranscriptomic regulator in cancer, influencing immune evasion and therapeutic resistance. This review synthesizes current evidence on FTO's roles in tumor biology.

Background

Cancer remains a leading cause of mortality, with therapeutic resistance and tumor heterogeneity posing significant challenges. Understanding the molecular mechanisms underlying tumor progression is essential. RNA modifications, particularly those mediated by FTO, have emerged as important factors in cancer biology.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

  • FTO functions as a context-dependent regulator in cancer, influencing tumor progression and immune evasion.
  • Its role in regulating PD-L1 expression is mediated through both direct and indirect mechanisms.
  • FTO's biological output is shaped by tumor lineage, subcellular localization, and competing m6A reader activities.
  • Emerging FTO inhibitors and combination strategies are evaluated based on preclinical evidence.
  • No FTO-targeted strategy has entered Phase I oncology evaluation as of now.

Clinical Implications

The context-dependent nature of FTO suggests variability in its role across different tumor types and microenvironments.

Conclusion

FTO represents a complex player in cancer biology, with implications for immune response and treatment resistance.

Related Resources & Content

  1. Frontiers in Medicine, 2026 -- Out“FOX”ing cancer: the implications of FOXC2 as a putative predictive biomarker for cancer immunotherapy
  2. Frontiers in Immunology, 2026 -- Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells
  3. Blood Cancer Journal -- Influence of T cell Features on the Efficacy of CAR-T Cell Therapy for Blood Cancers
  4. Frontiers in Immunology, 2026 -- Multifaceted regulation of thymic tolerance by pattern recognition cascades
  5. Journal for ImmunoTherapy of Cancer -- Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
  6. Frontiers in Immunology -- Epitranscriptomic control of cancer immunity and therapy resistance
  7. Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma | Journal for ImmunoTherapy of Cancer
  8. Cell Communication
  9. Frontiers | Epitranscriptomic control of cancer immunity and therapy resistance

Original Source(s)

Related Content